Table 2.
Patients’, CVC, and CRBSI characteristics of the PSM cohort (n = 3,024)
| Parameter | Men (n = 1,512) | Women (n = 1,512) | p value |
|---|---|---|---|
| Patients | |||
| Median age (95% CI), years | 60 (59–60) | 60 (59–61) | 0.91a |
| Underlying cancer, n (%) | 1.00b | ||
| Acute myeloid leukemia | 671 (44.4) | 671 (44.4) | |
| Multiple myeloma | 366 (24.2) | 366 (24.2) | |
| Non-Hodgkin lymphoma | 289 (19.1) | 289 (19.1) | |
| Acute lymphoblastic leukemia | 87 (5.8) | 87 (5.8) | |
| Hodgkin lymphoma | 23 (1.5) | 23 (1.5) | |
| Myeloproliferative neoplasm | 7 (0.5) | 7 (0.5) | |
| Myelodysplastic neoplasm | 15 (1.0) | 15 (1.0) | |
| Germ-cell tumor | 0 | 0 | |
| Sarcoma | 21 (1.4) | 21 (1.4) | |
| Carcinoma | 33 (2.2) | 33 (2.2) | |
| Neutropenia at CVC insertion, n (%) | 243 (16.1) | 240 (15.9) | 0.92c |
| Neutropenia at CRBSI diagnosis, n/N (%) | |||
| dCRBSI | 69/81 (85.2) | 52/62 (83.9) | 0.82c |
| dpCRBSI | 134/150 (89.3) | 86/101 (85.1) | 0.34c |
| Neutropenia at CVC removal, n (%) | 486 (32.1) | 459 (30.4) | 0.31c |
| CVCs | |||
| Anatomic site, n (%) | 1.00c | ||
| Internal jugular vein | 1,490 (98.5) | 1,490 (98.5) | |
| Subclavian vein | 22 (1.5%) | 22 (1.5%) | |
| CHG-coated CVC dressing, n (%) | 466 (30.8) | 466 (30.8) | 1.00c |
| Antimicrobial coated CVC, n (%) | 90 (6.0) | 90 (6.0) | 1.00c |
| Complicated CVC insertion, n (%) | 95 (6.3) | 95 (6.3) | 1.00c |
| CVC in situ time, days | |||
| Median (95% CI) | 14 (13–14) | 14 (13–14) | 1.00a |
| Range | 1–62 | 1–62 | |
| CRBSI | |||
| CRBSI rate, n (%) | |||
| dCRBSI | 81 (5.4) | 62 (4.1) | 0.12c |
| dpCRBSI | 150 (9.9) | 101 (6.7) | 0.002c |
| CRBSI incidence, x/1000 CVC days | |||
| dCRBSI | 3.8 | 2.9 | 0.11d |
| dpCRBSI | 7.0 | 4.7 | 0.002d |
| Time to CRBSI onset, days | |||
| dCRBSI | |||
| Median (95% CI) | 13 (11–15) | 13 (10–16) | 0.80a |
| Range | 3–62 | 1–34 | |
| dpCRBSI | |||
| Median (95% CI) | 12 (11–14) | 13 (11–14) | 0.72a |
| Range | 1–62 | 1–34 | |
| Causative CRBSI pathogens, n/N (%) | |||
| dCRBSI | 0.80b | ||
| CoNS | 60/81 (74.1) | 42/62 (67.7) | |
| Other Gram-positive bacteria | 9/81 (11.1) | 5/62 (8.1) | |
| Enterobacteriaceae | 6/81 (7.4) | 8/62 (12.9) | |
| Other Gram-negative bacteria | 2/81 (2.5) | 2/62 (3.2) | |
| Candida spp. | 2/81 (2.5) | 3/62 (4.8) | |
| Polymicrobial | 2/81 (2.5) | 3/62 (3.2) | |
| dpCRBSI | 0.27b | ||
| CoNS | 112/150 (74.7) | 70/101 (69.3) | |
| Other Gram-positive bacteria | 18/150 (12.0) | 12/101 (11.9) | |
| Enterobacteriaceae | 6/150 (4.0) | 10/101 9.9) | |
| Other Gram-negative bacteria | 3/150 (2.0) | 2/101 (2.0) | |
| Candida spp. | 2/150 (1.3) | 4/101 (4.0) | |
| Polymicrobial | 9/150 (6.0) | 3/101 (3.0) | |
CVC, central venous catheter; CHG, chlorhexidine gluconate gel pad; CRBSI, CVC-related bloodstream infection; PSM, propensity score matching; dCRBSI, definite CRBSI; dpCRBSI, definite plus probable CRBSI; 95% CI, 95% confidence interval.
aMann-Whitney U test.
bPearson χ2 test.
cFisher exact test.
dMid-P exact test.